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Syncope after myocardial infarction. Changes of the results of pro-
grammed ventricular stimulation during the last 26 years
Béatrice Brembilla-Perrot, Bérivan Azman, Nicolas Sadoul, Hugues
Blangy, Olivier Claudon, Karim Djaballah, Pierre Louis, Olivier Selton,
Lucian Muresan, Sonia Magalhes, Pierre Yves Zinzius, Arnaud Terrier De
La Chaise
CHU of Brabois, Cardiologie, Vandoeuvre Les Nancy, France
Ventricular tachycardia (VT) may explain syncope after myocardial infarc-
tion (MI) and is in this case is associated with a high risk of sudden death,
mainly in association with low left ventricular ejection fraction (LVEF). Pro-
grammed ventricular stimulation (PVS) remains the main method to look for
VT. The purpose of the study was to look for the changes of the population
referred for PVS for unexplained syncope after MI during the last 26 years.
Methods: 346 patients were recruited for unexplained syncope after MI
between 1982 and 2008: 76 patients (group I) were studied between 1982 and
1989; 151 patients (group II) were studied between 1990 and 1999 and 119
patients (group III) were studied between 2000 and 2008. ECG and 24 hour
Holter monitoring did not indicate a possible cause of syncope. LVEF was
evaluated in all patients by echocardiography. PVS was systematic with the
same protocol (up to 3 extrastimuli in 2 sites of right ventricle).
Results: Clinical and electrophysiological data were similar between
groups I and II but differed significantly in group III: age was higher in group
III (68±12 years) than in group I (64±11) and II (65±12) (p <0.009); LVEF
was higher in group III (45±13%) than in group I (41±16) and II (42±13)
(p<0.008). PVS was more frequently negative in group III (74%) than in group
I (43%) and II (54 %) (p<0.001). Monomorphic VT < 270 b/min was less fre-
quently induced in group III (16 %) than in group I (30 %) and II (26 %)
(p<0.01). Ventricular flutter (VT > 270/min) and ventricular fibrillation were
less frequently induced in group III (9 %) than in group I (26 %) and II (19
%) (p<0.05).The changes could be related to the ICD implantation recommen-
dations and to recanalization of occluded coronary artery, which is systematic
in recent MI since 2000 (38 % in group III, 27 % in groups I and II) (p <0.05).
Conclusions: Clinical data and results of PVS in patients admitted for
unexplained syncope after MI infarction were identical between 1982 and 199
and have changed since 2000; patients are older and had relatively preserved
LVEF. Therefore, the induction of a ventricular tachyarrhythmia is rarer than
before the year 2000.
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Comparison of Omeprazole and Pantoprazole Influence on Clopido-
grel Effect of a High 150 mg Maintenance Dose: the Proton pomp
inhibitors and Clopidogrel Association (PACA) prospective, randomi-
zed study
Thomas Cuisset (1), Corinne Frere (2), Jacques Quilici (3), Raphael Poyet
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Haematology, Marseille, France – (3) CHU Timone, Department of Car-
diology, Marseille, France – (4) Inserm, U626, Faculté de Médecine,
Laboratoire d’Hématologie, Marseille, France
Objective: To compare the effect of two Proton Pomp Inhibitors (PPI) on
platelet response to clopidogrel after coronary stenting for Non ST Elevation
Acute Coronary Syndrome (NSTE ACS).
Background: Use of omeprazole has been reported to decrease signifi-
cantly the clopidogrel antiplatelet effect because of cytochrome P450 interac-
tion. As all PPIs are metabolized by CYP2C19, but to a varying degree, we
hypothesized that the reported negative omeprazole-clopidogrel drug interac-
tion may not be due to a class effect.
Methods and Results: 104 patients undergoing coronary stenting for
NSTE ACS were prospectively included and randomized to omeprazole or
pantoprazole 20 mg. They received at discharge 75 mg aspirin and 150 mg
clopidogrel. Platelet reactivity index VASP was used to assess clopidogrel res-
ponse and ADP-induced aggregation for platelet reactivity (ADP-Ag). After
one month, patients receiving pantoprazole had a significantly better platelet
response to clopidogrel as assessed with the PRI VASP: 36±20 % vs 48±17 %,
p=0.007. We identified more clopidogrel non responders in the omeprazole
group than in the pantoprazole group: 44% vs 23%, p=0.04, OR 2.6 [1.2-6.2].
Conversely, we did not observe any significant difference in platelet reactivity
with ADP-Ag between omeprazole and pantoprazole groups: 52±15 % and
50±18 % respectively, p=0.29.
Conclusion: The present findings suggest the preferential use of pantopra-
zole compared to omeprazole in patients receiving clopidogrel to avoid any
potential negative interaction with CYP2C19.
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Comparison of the Angiographic Myocardial Blush Grade with
Delayed Enhanced Cardiac Magnetic Resonance for the assessment of
Microvascular Obstruction in Acute Myocardial Infarctions
Jacques Vicente, Nathan Mewton, Pierre Croisille, Patrick Staat, Eric
Bonnefoy, Michel Ovize, Didier Revel
Hopital Cardiovasculaire Louis Pradel, Cardiologie, Bron, France
Background: Myocardial Blush Grade (MBG) and cardiac magnetic reso-
nance (CMR) are both imaging tools that can assess myocardial reperfusion
after primary percutaneous coronary intervention (PCI) for acute myocardial
infarction (AMI).
Objectives: We studied the relation between MBG and gadolinium-
enhanced CMR for the assessment of microvascular obstruction (MVO) in
patients with acute ST-elevated myocardial infarction (STEMI) treated by pri-
mary PCI.
Material and Methods: MBG was assessed in 39 patients with initial
TIMI 0 STEMI successfully treated by PCI, resulting in TIMI 3 flow grade
and complete ST-segment resolution. These MBG values were related to
MVO determined by CMR, performed between 2 and 7 days after PCI. Left
ventricular (LV) volumes were determined at baseline, and at 6-month follow
up.
Results: No statistical relation was found between MBG and MVO extent
at CMR (p=0.63). Regarding MBG 0 and 1 as a sign of MVO, the sensitivity
and specificity of these scores were respectively 53.8% and 75%. In this study,
CMR determined MVO was the only significant LV remodeling predicting
factor (_=31.8; p=0.002), whatever the MBG status was.
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Conclusion: MBG underestimates MVO after an optimal revascularization
in AMI compared to CMR. This study suggests the superior accuracy of
delayed enhanced magnetic resonance (DEMR) over MBG for the assessment
of myocardial reperfusion injury which is needed in clinical trials where the
principal endpoint is the reduction of infarct size (IS) and MVO. 
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The relative contribution of the CYP2C19*2 polymorphism in the low
responsiveness to clopidogrel in the VASP-02 study
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The CYP2C19*2 genetic variant is known to contribute to low responsive-
ness to clopidogrel treatment, leading to a higher rate of cardiovascular events.
Systematic identification of the 2C19*2 carriers to predict the individual
patient’s response to clopidogrel is a matter of debate.
Data of the VASP-02 study comparing patients’ responsiveness to 75 and
150 mg/day maintenance dose of clopidogrel (Aleil et al., J Am Coll Cardiol
Intv 2008) were reanalyzed by determining the 2C19*2 carrier status of the
patients. Platelet reactivity index (PRI) was determined using the VASP
method. A PRI>69 % defines low responsiveness to clopidogrel.
In the 37 non responder patients, 42.4 % were 2C19*2 carriers versus 22.0
% in the responder patients (p=0.022). After multivariate analysis, 2C19*2
polymorphism and high body weight were two independent predictors of high
PRI (odds ratio [95% confidence interval] 3.39 [1.06-10.84] p=0.039 and 3.14
[1.19-8.30] p=0.021) respectively. Increasing the maintenance dose of clopido-
grel from 75 to 150 mg/day in non responder patients resulted in a significant
decrease of PRI from 76.4±4.6 to 62.8±10.4 % (p<0.01) in 2C19*2 carriers
and from 76.1±5.3 to 60.8±13.4 % (p<0.01) in non carriers. The mean
decrease of PRI after doubling the dose was not significantly different between
carriers and non carriers of the genetic variant (-13.6±9.3 and -15.3±11.8 %
p=0.39, respectively).
CYP2C19*2 is an important determinant of the responsiveness to clopido-
grel while other independent factors such as body weight also are involved.
Hyporesponsiveness in 2C19*2 carriers can be easily overcome by doubling
the maintenance dose of clopidogrel. Thus, combined functional pharmacody-
namic monitoring and genetic determination of CYP profile should help
improve patient’s responsiveness to clopidogrel.
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Introduction: Numerous biological studies have reported inter-individual
variability in platelet response to clopidogrel with clinical relevance. High
Post treatment platelet reactivity (ADP-induced aggregation >70%) has been
proposed to define Non response to clopidogrel. We assessed in clopidogrel
non responders undergoing elective percutaneous coronary intervention (PCI)
the benefit of adjusted antiplatelet therapy with glycoprotein IIbIIIa (GPII-
bIIIa) antagonist administration during PCI for one month clinical outcome.
Methods and Results: 149 clopidogrel non-responders referred for elec-
tive PCI were prospectively included and randomized to “conventional group”
(n=75) or “active group” with GPIIbIIIa antagonist (n=74). All patients
received 250 mg aspirin and 600 mg clopidogrel before PCI and platelet tes-
ting. The rate of CV events at one month was significantly lower in the “active
group” than in the “conventional group”: 19% (n=14) vs. 40% (n=30),
p=0.006, [OR (95%CI): 2.8(1.4-6.0)]. No patient in either group had post pro-
cedural TIMI major bleeding or required transfusions.
Conclusion: The present study suggested benefit of tailored antiplatelet
therapy during elective PCI with GPIIbIIIa antagonist for clopidogrel non res-
ponders without increased bleeding risk.
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Slow Response to Clopidogrel Predicts Low Response
Anne Bellemain-Appaix, Gilles Montalescot, Johanne Silvain, Olivier
Bathelemy, Farzin Beygui, Jean-Philippe Collet – Hopital Pitié Salpe-
trière, Cardiologie, Paris, France
Objectives: To determine if the speed of response to clopidogrel loading
predicts the final degree of response to clopidogrel.
Background: Fast inhibition of platelet aggregation is important in the set-
ting of ACS and PCI, but its relation to the final degree of inhibition is not
well established.
Methods: We performed a post-hoc analysis of ALBION, which included 103
NSTE-ACS patients randomised to 300, 600 or 900mg LD of clopidogrel. Early
kinetic profiles of ADP 20μmol/l Maximal Platelet Aggregation (MPA) and del-
taMPA (with baseline sample as reference) were studied, with 8 time points within
the 24 hours following loading. Low response was defined as deltaMPA<10%
p=0.006
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